478-84-2
478-84-2
Chemical Structure
2-Bromo-LSD
Synonym(s): BOL-148; Bromolysergide
- CAS. Nr.: 478-84-2
- Formula:C20H24BrN3O
- Molecular Weight:402.33
IUPAC Name: (6aR,9R)-5-bromo-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
InChIKey: VKRAXSZEDRWLAG-SJKOYZFVSA-N
SMILES: [H][C@]1(C2)N(C[C@@H](C=C1C3=CC=CC4=C3C2=C(N4)Br)C(N(CC)CC)=O)C
Biological Activity: 2-Bromo-LSD (BOL-148) is a blood-brain barrier-permeable 5-HT2A partial agonist and competitive partial antagonist. 2-Bromo-LSD acts as both a potent partial agonist (with an EC50 of 0.81 nM for Gq dissociation) and a potent partial antagonist (with a KB of 0.18 nM for Gq dissociation) at the 5-HT2A receptor. 2-Bromo-LSD exhibits partial agonist activity at multiple aminergic GPCRs, including 5-HT2A. 2-Bromo-LSD lacks 5-HT2B agonist activity. 2-Bromo-LSD induces dendritogenesis and spinogenesis. 2-Bromo-LSD reverses the behavioral effects of chronic stress and increases active coping behaviors in mice[1][2].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
2-Bromo-LSD | 97.26% | 2-Bromo-LSD (BOL-148) is a blood-brain barrier-permeable 5-HT2A partial agonist and competitive partial antagonist. 2-Bromo-LSD acts as both a potent partial agonist (with an EC50 of 0.81 nM for Gq dissociation) and a potent partial antagonist (with a KB of 0.18 nM for Gq dissociation) at the 5-HT2A receptor. 2-Bromo-LSD exhibits partial agonist activity at multiple aminergic GPCRs, including 5-HT2A. 2-Bromo-LSD lacks 5-HT2B agonist activity. 2-Bromo-LSD induces dendritogenesis and spinogenesis. 2-Bromo-LSD reverses the behavioral effects of chronic stress and increases active coping behaviors in mice. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Bromerguride | Bromerguride (2-Bromolisuride) is an analogue of the ergot dopamine agonist Lisuride (HY-12713). Bromerguride exhibits central antidopaminergic properties. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
LEK 8841 methanesulfonate | LEK 8841 methanesulfonate is a gastrointestinal calming agent with strong selective 5-HT2 receptor antagonist activity. The antipsychotic potential of LEK 8841 has made it the focus of research into alternative medicines. LEK 8841 behaves as a pure competitive antagonist in response to 5-HT and norepinephrine, with pA2 values of 7.93 and 6.45, respectively. The selectivity of LEK 8841 is better than that of the comparative drug ketanserin, making it an important reference value in corresponding receptor research. Studies related to structural modifications have shown that LEK 8841 exhibits high affinity for 5-HT2 receptors and low alpha-adrenergic receptor activity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
LEK 8804 | LEK 8804 is a compound with 5-HT1A receptor agonist and 5-HT2 receptor antagonist properties, and has the activity of modulating related receptor-mediated behavioral responses. LEK 8804 can induce spontaneous tail-flick response in rats in a dose-dependent manner, showing complete 5-HT1A agonist activity, and can inhibit 5-HTP-induced head twitch response in mice, probably through antagonism of 5-HT2 receptors rather than agonism of 5-HT1A receptors. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lisuride | 99.85% | Lisuride is an orally active dopamine D2 receptors agonist. Lisuride, as an ergot derivative, can be used for the research of Parkinson's disease, migraine, and high prolactin levels. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ALD-52 | ALD-52 (1-Acetyl-LSD) is a prodrug for LSD. ALD-52 shows an affinity to 5-HT1A, 5-HT2A and 5-HT2C with a sub>D values of 1054, 174 and 10.2 nM, respectively. ALD-52 is converted to LSD and induces a head-twitch response (HTR) in vivo. ALD-52 can be used for hallucinogen research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ECPLA | ECPLA, a lysergamide lysergic acid diethylamidean (LSD) analog, is a potent 5-HT2A agonist (EC50 of 14.6 nM) for Gq-mediated calcium flux. ECPLA has high affinity for most serotonin receptors, α2-adrenoceptors, and D2-like dopamine receptors. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N-Allylnoriso-LSD | N-Allylnoriso-LSD (6-Allyl-6-norisolysergic acid diethylamide) is a lysergamide. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ETH-LAD | ETH-LAD (N-Ethyl-nor-LSD) is an activator for 5-HT2A receptor with Ki of 5.1 nM. ETH-LAD exhibits affinity for dopamine receptor D1 and dopamine receptor D2 with Ki of 22.1 nM and 4.4 nM. ETH-LAD acts as psychoactive substance in rat model. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
AL-LAD | AL-LAD is a 5-HT2A receptor ligand with rat Ki values of 8.1 nM and 3.4 nM. AL-LAD mediates behavioral responses characteristic of serotonergic psychedelics. AL-LAD induces the head-twitch response in male C57BL/6J mice in an inverted-U-shaped dose-dependent manner. AL-LAD exhibits LSD-like behavioral effects in male C57BL/6J mice. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Persson SA. The effect of LSD and 2-bromo LSD on the striatal DOPA accumulation after decarboxylase inhibition in rats. Eur J Pharmacol. 1977 May 1;43(1):73-83. [Content Brief]
- [2]. Lewis V, et al. A non-hallucinogenic LSD analog with therapeutic potential for mood disorders. Cell Rep. 2023;42(3):112203. [Content Brief]
